Atea Pharmaceuticals (Atea Pharmaceuticals) 3-Year Book Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Atea Pharmaceuticals 3-Year Book Growth Rate?

Atea Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $6.65.

During the past 12 months, Atea Pharmaceuticals's average Book Value per Share Growth Rate was -13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Competitive Comparison of Atea Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Atea Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atea Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's 3-Year Book Growth Rate falls into.

Atea Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Atea Pharmaceuticals (NAS:AVIR) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Atea Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Atea Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Atea Pharmaceuticals (Atea Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atea Pharmaceuticals Inc (NAS:AVIR) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Franklin Street, Suite 2100, Boston, MA, USA, 02110

Website

https://www.ateapharma.com

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Executives

Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Jerome M. Adams	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp	10 percent owner	190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Jean-pierre Sommadossi	director, 10 percent owner, officer: President, CEO, and Chairman	125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Jpm Partners Llc	10 percent owner	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Chung K. Chu	10 percent owner	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Janet Mj Hammond	officer: Chief Development Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Isaac Cheng	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
John Vavricka	officer: Chief Commercial Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruno Lucidi	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Maria Arantxa Horga	officer: Acting Chief Medical Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruce Polsky	director	C/O VISION-SCIENCES, INC., 40 RAMLAND ROAD, ORANGEBURG NY 10962